Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer
Metadatos
Mostrar el registro completo del ítemAutor
Martín Blázquez, Ariadna; Díaz, Caridad; González Flores, Encarnación; Franco Rivas, Daniel; Jiménez Luna, Cristina; Melguizo Alonso, Consolación; Prados Salazar, José Carlos; Genilloud Rodríguez, Olga; Vicente, Francisca; Caba Pérez, Octavio; Pérez del Palacio, JoséEditorial
Springer Nature
Fecha
2019Referencia bibliográfica
Martín-Blázquez, A., Díaz, C., González-Flores, E., Franco-Rivas, D., Jiménez-Luna, C., Melguizo, C., ... & del Palacio, J. P. (2019). Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer. Scientific Reports, 9(1), 1-9.
Patrocinador
This study was supported by a grant (n° 15CC056/DTS17/00081- ISCIII-FEDER) from the Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO) and Roche Pharma S.L. Authors from the Fundación MEDINA acknowledge the receipt of financial support from this public-private partnership of Merck Sharp & Dohme de España S.A. with the University of Granada and Andalusian Regional Government (PIN-0474-2016).Resumen
Colorectal cancer is one of the main causes of cancer death worldwide, and novel biomarkers are
urgently needed for its early diagnosis and treatment. The utilization of metabolomics to identify
and quantify metabolites in body fluids may allow the detection of changes in their concentrations
that could serve as diagnostic markers for colorectal cancer and may also represent new therapeutic
targets. Metabolomics generates a pathophysiological ‘fingerprint’ that is unique to each individual.
The purpose of our study was to identify a differential metabolomic signature for metastatic colorectal
cancer. Serum samples from 60 healthy controls and 65 patients with metastatic colorectal cancer were
studied by liquid chromatography coupled to high-resolution mass spectrometry in an untargeted
metabolomic approach. Multivariate analysis revealed a separation between patients with metastatic
colorectal cancer and healthy controls, who significantly differed in serum concentrations of one
endocannabinoid, two glycerophospholipids, and two sphingolipids. These findings demonstrate that
metabolomics using liquid-chromatography coupled to high-resolution mass spectrometry offers a
potent diagnostic tool for metastatic colorectal cancer.